Harnessing Apoptosis in AML

The treatment landscape for AML has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML continues to be explored.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 3, 2021 Category: Hematology Authors: Kapil Saxena, Courtney DiNardo, Naval Daver, Marina Konopleva Source Type: research